ICELAND
CERVICAL CANCER PROFILE

Morbidity and Mortality

Crude cervical cancer incidence per 100 000 women (2020): 9.4
Age-standardized cervical cancer incidence per 100 000 women (2020): 8.3
Cumulative risk of cervical cancer, ages 0-74 (2020): 0.7%
Cervical cancer deaths (2019): 9
Cervical cancer mortality-to-incidence ratio (2020): 0.31
Population-based cancer registry exists (2021): Yes

Primary Prevention

HPV vaccination programme coverage among girls (2020)
Programme coverage:
Coverage by age 15:

<table>
<thead>
<tr>
<th>% of target population</th>
<th>first dose</th>
<th>final dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>0%</td>
<td>90%</td>
<td>91%</td>
</tr>
<tr>
<td>20%</td>
<td>80%</td>
<td>84%</td>
</tr>
<tr>
<td>40%</td>
<td>70%</td>
<td>74%</td>
</tr>
<tr>
<td>60%</td>
<td>60%</td>
<td>62%</td>
</tr>
<tr>
<td>80%</td>
<td>50%</td>
<td>52%</td>
</tr>
<tr>
<td>100%</td>
<td>40%</td>
<td>42%</td>
</tr>
</tbody>
</table>

HPV vaccination programme (2020):
HPV included in national vaccination programme: Yes
Scale of vaccination programme: National
Year of introduction: 2011
Primary target cohort: 12 years

Related risk factors:
Tobacco use prevalence, women aged 15+ years (2020)**: 12%
Condom use at last high-risk sex (-): ND
HIV incidence per 1000, women aged 15+ years (2020): 0.03

Secondary Prevention

National screening programme for cervical cancer exists (2021): Yes
Primary screening test used (2021): cytology
Target age range of programme (2021): 23-65 years
Programme/guidelines exist to strengthen early detection of first symptoms at primary health care level (2021): Yes
Clearly defined referral system exists from primary care to secondary and tertiary care (2021): Yes

Treatment and Supportive Care

National guidelines on cervical cancer management exist (2021): Yes

Cancer diagnosis and treatment services generally available (2021):
Cancer centre or cancer department at tertiary level: Yes
Pathology services (laboratories): Yes
Cancer surgery: Yes
Chemotherapy: Yes
Radiotherapy: Yes

Palliative care for patients with NCDs in the public health system generally available (2021):
In primary health care facilities: No
In community or home-based care: Yes

WHO Cervical Cancer Elimination Strategy Targets for 2030

90% of girls fully vaccinated with the HPV vaccine by the age of 15
70% of women are screened with a high-performance test by 35 years of age and again by 45 years of age
90% of women identified with cervical disease receive treatment

Reported annual opioid consumption — excluding methadone — in oral morphine equivalence per capita (2017): 359mg

**Data refer to tobacco smoking only, in absence of sufficient data on all tobacco use

ND = data not available

* Programme coverage: % of national target population (among 9-14-year-old girls)
† Coverage by age 15: % of population turning 15 that have been vaccinated against HPV at any time between ages 9 to 14

See Explanatory Notes for indicator descriptions.